Subscribe
Under terms of the deal, Stoke will spearhead global development of zorevunersen, while Biogen will receive exclusive rights to commercialize the treatment outside of North America.
Epitopea Strikes Research Collaboration with Merck, Appoints Klaus Edvardsen as Chief Medical Officer
2025 Pipeline Report: The Edge of Greatness?
Teva Agrees to Strategic Partnerships with Formycon AG, Klinge Biopharma, & Samsung Bioepis
